Antibody Ingredients TRIZ Cases

Segmenting the HER2 extracellular domain enables antibodies to block dimerization while enhancing internalization efficiency across varying expression levels.

Anti-TNFR2 antibody modulates immune response to enhance graft-versus-leukemia activity while preventing hematologic malignancy relapse.

Modified CD38 antibodies with targeted Fc mutations deliver enhanced cytotoxicity and enzyme inhibition.

Combining antiandrogens with PSMA ligand conjugates overcomes therapeutic resistance in hormone-refractory prostate cancer.

Segmented antibody combinations reduce toxicity to normal cells while maintaining treatment efficacy against chemoresistant solid tumors.

Linker attachment via sulfhydryl group enhances tumor selectivity, reducing toxic side effects while maintaining anti-tumor activity.

Anti-CD94 antibodies deplete natural killer cells, preventing their killing of activated T cells and improving T cell-mediated cancer elimination.

Bispecific antibodies bind PD-L1 and 4-1BB to activate intra-tumoral T-cells.

Segmented VH and VL domains prevent off-target radiation exposure without clearing agents, simplifying treatment protocols.

Anti-CD45 antibodies remove endogenous immune cells, eliminating immunostimulatory functions that impede hematopoietic stem cell transplantation.

Withdrawing statins restores serum cholesterol, enabling antibody binding and complement-dependent cytotoxicity against B cell lymphoma.

Antibody-drug conjugates deliver cytotoxic payloads via IL11RA targeting to overcome drug resistance and improve treatment efficacy.

Antibodies targeting SSEA4, GloboH, and SSEA3 overcome glioblastoma resistance by inducing antibody-dependent cellular cytotoxicity.

Segmenting antibody responses into polyclonal products from transgenic ungulates resolves the trade-off between binding specificity and therapeutic efficacy.

Antibody-drug conjugates target B7H6-expressing tumor cells to induce cytotoxicity while managing formulation complexity.

Antigen binding proteins inhibit HER3 receptor activity, reducing tumor growth and overcoming acquired resistance mechanisms.

Specific antibody binding isolates modified LDL immune complexes from serum, resolving interference from pre-formed complexes to improve diagnostic reliability.

Protease-cleavable linkers reduce systemic toxicity and soluble MSLN interference while enhancing plasma stability.

Segmented antibody-drug conjugates target B7-H4 antigens on cancer cells, reducing systemic toxicity while improving patient response rates.

A fully human anti-PCSK9 monoclonal antibody achieves high binding affinity through segmented light and heavy chain CDR screening.

G250-specific antibodies target micrometastases to reduce recurrence risk while avoiding toxic side effects of conventional adjuvant therapies.

Monoclonal antibodies bind CXCR4 receptors and induce conformational changes in homodimers.

Ankyrin repeat domain proteins replace monoclonal antibodies to resolve treatment resistance and safety concerns in acute myeloid leukemia therapy.

Bufalin-specific antibodies neutralize enzyme inhibitors to restore cellular homeostasis during hemorrhagic shock.

Intermediate CD3 binding affinity reduces cytokine release syndrome risk while maintaining therapeutic efficacy.

VHH polypeptides bind canine PD-1 to block immune checkpoint signaling, reducing Fc receptor interactions that limit therapeutic efficacy.

Measuring PD-L1 and TIGIT on exosomes predicts therapy response, avoiding ineffective treatment when tumor-derived proteins overwhelm the immune system.

Removing fucose residues from anti-PSMA antibodies eliminates glycan interference, boosting cytotoxic potency without conjugating chemotherapeutic agents.

Continuous intravenous priming infusion followed by bolus dosing reduces peak serum concentrations and cytokine release syndrome in cancer patients.

Specific dosing of humanized anti-α4β7 antibodies blocks T cell trafficking to prevent acute graft-versus-host disease after stem cell transplantation.

Agents targeting TGF-beta signaling and gap junctions disrupt tumor microtube networks, overcoming treatment resistance in glioblastoma.

Humanized anti-CDH6 antibody drug conjugates utilize optimized linkers to deliver cytotoxic payloads, addressing safety and efficacy gaps in existing therapies.

Site-specific PEG attachment on anti-CD3 antibodies extends serum half-life while maintaining bioactivity lost in random polymerization.

Adapting human antibody sequences accelerates veterinary cancer therapy development while maintaining therapeutic efficacy.

Combining FcγRIIb-blocking antibodies with CTLA-4 binders alters immune receptor activation ratios to enhance therapeutic activity.

A bispecific antibody binds PD-L1 and CD137 to activate T cells.

Segmented B7-H3 and PD-1 antibodies overcome tumor microenvironment suppression, improving immune efficacy for various cancers.

Combining avasimibe with checkpoint inhibitors enhances CD8+ T cell cytotoxic activity.

Optimized anti-OX40 antibody fragments activate T cells while preserving the native OX40-OX40L interaction.

Urea linkers attach amatoxins to antibodies at the tryptophan 1'-N atom, preventing premature plasma release and reducing liver toxicity.

Site-specific conjugation at antibody position 442 resolves lysine-linked heterogeneity, improving therapeutic index and tolerability.

An anti-CD38 F(ab')2 fragment binds to natural killer cells to shield them from antibody-dependent cell-mediated cytotoxicity.

Benralizumab depletes eosinophils via antibody-dependent cell cytotoxicity to improve asthma control.

Engineered CDR mutations boost LAG-3 binding affinity, resolving the trade-off between clinical efficacy and toxic side effects.

Combines oncolytic parvovirus H-1 with anti-PD1 antibodies to enhance T cell infiltration into tumors.

Anti-TIGIT antibodies deplete regulatory T cells and block ligand binding to overcome tumor immunosuppression.

Asymmetric multimeric molecules reduce cytokine release syndrome while maintaining tumor cell elimination.

Humanized low-affinity anti-IgE antibodies bind IgE without triggering mast cell degranulation.

Photoactive antibodies incorporate photocaged amino acids into antigen binding sites to enable light-controlled target engagement.

Anti-CD117 antibody depletes hematopoietic stem cell niches, enabling donor engraftment without myeloablative conditioning toxicity.